Chinese contract drugmaker Pharmaron plans HK listing to raise around $500m

Chinese contract drugmaker Pharmaron plans HK listing to raise around $500m

Photographer: Justin Chin/Bloomberg

Pharmaron Beijing Co. is planning a Hong Kong share sale only six months after the contract drugmaker went public in China, according to people with knowledge of the matter.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter